ABBV vs ORCL: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Oracle Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Oracle Corporation · Technology
$175.08
+45.0% upside to fair value
Grade C
High Quality
QuantHub Verdict
ORCL has more upside to fair value
(+45.0%).
ORCL trades at a lower forward P/E
(30.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
ORCL |
| Current Price |
$197.69 |
$175.08 |
| Fair Value Estimate |
$210.22 |
$253.87 |
| Upside to Fair Value |
+6.3%
|
+45.0%
|
| Market Cap |
$349.7B |
$503.5B |
| Forward P/E |
83.3x
|
30.8x
|
| EV / EBITDA |
23.4x
|
21.4x
|
| Price / Sales |
5.7x
|
7.9x
|
| Price / FCF |
18.7x
|
-20.4x
|
| Revenue Growth YoY |
+10.0%
|
+21.7%
|
| Gross Margin |
70.2%
|
66.4%
|
| Operating Margin |
26.7%
|
30.8%
|
| Return on Equity |
-361.6%
|
57.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
—
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Oracle Corporation is a leading enterprise software and cloud infrastructure provider with a strong legacy in database technology and a growing cloud business. The company benefits from a durable competitive moat supported by high insider ownership, experienced leadership, and a history of strategic acquisitions. Oracle's recent financials show robust revenue growth of 21.7% and earnings growth o…
Accumulation Zones
| Metric |
ABBV |
ORCL |
| Zone Low |
$157.66 |
$190.40 |
| Zone High |
$178.69 |
$215.79 |
| In Buy Zone? |
No
|
Yes
|